Accéder au contenu
Merck

Supracor hyperopia and presbyopia correction: 6-month results.

European journal of ophthalmology (2013-09-24)
Cemile Banu Cosar, Asim Bozkurt Sener
RÉSUMÉ

To investigate refractive and visual outcomes and complications of the Supracor procedure to treat presbyopia. A total of 123 eyes from 68 presbyopic patients with hyperopia were enrolled in this prospective, nonrandomized, clinical trial. The Supracor procedure was performed using the Technolas excimer laser 217P (Technolas Perfect Vision GmbH). Follow-up eye examinations were performed at postoperative day 1, month 1, and month 6. All 123 surgeries were uneventful. At 6 months postoperatively, uncorrected distance visual acuity was 20/20 or better in 27 (22.0%) eyes and 20/25 or better in 45 (36.6%) eyes. At 6 months postoperatively, 35 (28.5%) eyes lost 1 line and 13 (10.6%) eyes lost 2 lines of corrected distance visual acuity (CDVA). At 6 months postoperatively, uncorrected near visual acuity was 20/20 or better in 95 (77.2%) eyes and 20/25 or better in 110 (89.4%) eyes. At 6 months postoperatively, 6 (4.9%) eyes lost 1 line of corrected near visual acuity. The Supracor presbyopia procedure showed good near visual acuity outcomes over 6 months follow-up but loss of CDVA occurred in 39.1% of eyes.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Moxifloxacin hydrochloride, VETRANAL®, analytical standard
Moxifloxacin hydrochloride, European Pharmacopoeia (EP) Reference Standard